Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients.

@article{Mulens2010ImmunogenicityAS,
  title={Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients.},
  author={Vladimir Mulens and Ana de la Torre and Patricia Marinello and Ronald Becerra Rodr{\'i}guez and Jorge Eliecer Nunez Cardoso and Ren{\'e} Henr{\'i}quez D{\'i}az and Miguel O'Farrill and Amparo Gonz{\'a}lez Mac{\'i}as and Carmen Elena Viada and Giselle Saurez and Adriana Carr and Tania Crombet and Zaima Mazorra and Rolando Gual P{\'e}rez and Luis E. Fern{\'a}ndez},
  journal={Human vaccines},
  year={2010},
  volume={6 9}
}
Increased levels of NeuGc-containing gangliosides have been described in human breast cancer. A controlled Phase II clinical trial was conducted in patients with metastatic breast cancer to evaluate immunogenicity, safety and to identify evidences of biological activity of a cancer vaccine composed by NeuGcGM3 in a proteoliposome of Neisseria meningitidis together with Montanide ISA 51 as adjuvant. After first line chemotherapy, 79 women were randomized 1:1 to receive the vaccine candidate or… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine.

  • Human vaccines & immunotherapeutics
  • 2014
VIEW 4 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese.

  • Oral diseases
  • 2012
VIEW 3 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED